Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04615715 · ClinicalTrials.gov registry record · NA
Prenatal Behavioral Intervention to Prevent Maternal Cytomegalovirus (CMV) in Pregnancy
A NA study of Maternal Cytomegalovirus Infections and Cytomegalovirus Congenital, sponsored by University of Alabama at Birmingham.
- Active
- Registry status
- NA
- Development phase
- 840
- Enrollment target
- 1
- Study location
NCT04615715: Active NA study of Maternal Cytomegalovirus Infections and Cytomegalovirus Congenital, sponsored by University of Alabama at Birmingham.
NCT04615715 is a NA study of Maternal Cytomegalovirus Infections and Cytomegalovirus Congenital that is active but no longer recruiting, run by University of Alabama at Birmingham. The registered enrollment target is 840 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (40% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04615715, a NA study of Maternal Cytomegalovirus Infections and Cytomegalovirus Congenital, is active but no longer recruiting, sponsored by University of Alabama at Birmingham.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 840 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate whether a brief prenatal clinic-based cytomegalovirus (CMV) risk-reduction behavioral intervention will prevent maternal CMV infections during pregnancy in women.
Primary Outcome
CMV seroconversion is defined as the development of CMV immunoglobulin G (IgG) antibody in the serum of women who did not have antibodies previously. The CMV seroconversion rate will be assessed in participants.
Conditions Studied
Interventions
- BEHAVIORAL CMV Risk-Reduction Intervention
- BEHAVIORAL Stress Reduction Messaging
Study Locations (1)
Alabama
- University of Alabama at Birmingham - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 840 participants |
| Start Date | 2021-01-11 |
| Est. Completion | 2026-03 |
| Phase | NA |
What the registry record for NCT04615715 still lists
NCT04615715 is an interventional study that assigns participants to a tested intervention. The registered 840 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (40% lower).
The record links to 2 conditions, with Maternal Cytomegalovirus Infections appearing as the primary indexed condition, and to 2 interventions - of which CMV Risk-Reduction Intervention is the first listed.
NCT04615715 reports a single indexed study location in Alabama.
Frequently Asked Questions
What is clinical trial NCT04615715 about?
NCT04615715 is a clinical study titled "Prenatal Behavioral Intervention to Prevent Maternal Cytomegalovirus (CMV) in Pregnancy". This study will evaluate whether a brief prenatal clinic-based cytomegalovirus (CMV) risk-reduction behavioral intervention will prevent maternal CMV infections during pregnancy in women.
What is the current status of trial NCT04615715?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 840 participants. The study started on 2021-01-11. Estimated completion is 2026-03.
What conditions does trial NCT04615715 study?
This clinical trial studies the following conditions: Maternal Cytomegalovirus Infections, Cytomegalovirus Congenital.
What interventions are being tested in trial NCT04615715?
The interventions under investigation include: CMV Risk-Reduction Intervention (BEHAVIORAL), Stress Reduction Messaging (BEHAVIORAL).
Who is sponsoring clinical trial NCT04615715?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04615715 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04615715's enrollment target sits among peer trials
840 133rd of 2000 higher than 1,867 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04831580 · 840 participants · NA
A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer
- NCT04976881 · 840 participants · NA
Promoting Preconception Care and Diabetes Self-Management Among Reproductive-Aged Women With Diabetes
- NCT04985903 · 840 participants · NA
Baby Steps III: Testing a Clinician and Patient Intervention to Promote Smoking Cessation Among Pregnant Women
- NCT05384626 · 840 participants · Phase 1
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI